SURF - サ―フェイス・オンコロジ― （Surface Oncology Inc.） サ―フェイス・オンコロジ―SURFのチャート
SURFの企業情報
| symbol | SURF |
|---|---|
| 会社名 | Surface Oncology Inc （サ―フェイス・オンコロジ―） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Biological Products (No Diagnostic Substances) |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Surface Oncology Inc. is a clinical-stage immuno-oncology company. The Company is engaged in the development of cancer immunotherapies. To unlock the potential of cancer immunotherapy the Company is targeting a set of immune processes by which cancer cells evade immune recognition and attack. Its programs are built upon insights about how to improve the immune system’s recognition and elimination of cancer cells. These include approaches to improve the effectiveness of antigen presentation to the adaptive immune system to block the activity of a range of suppressor cells in the tumor microenvironment and to counter the immunosuppressive environment that selectively accumulates in and around the tumor. By targeting the interface of innate and adaptive immunity it hopes to expand the reach of cancer immunotherapy to patients in need of treatment. サ―フェイス・オンコロジ―は米国のバイオ医薬品企業。臨床段階で、がん治療における免疫療法の開発に従事する。免疫抑制腫瘍微小環境における専門知識を、がん治療の開発に用いる。同社候補薬はタンパク質を標的とするSRF231、CD73を阻害するSRF373、インタ―ロイキンを標的とするSRF388などである。本社所在地はマサチュ―セッツ州ケンブリッジ。 Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. Its pipeline includes two wholly-owned clinical-stage programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting regulatory T cells via targeting CCR8 (SRF114). In addition, Surface has two partnerships with major pharmaceutical companies: a collaboration with Novartis targeting CD73 (NZV930; Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813; preclinical). Surface's novel cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies. |
| 本社所在地 | 50 Hampshire Street 8th Floor Cambridge MA 02139 USA |
| 代表者氏名 | Daniel S. Lynch ダニエルS.リンチ |
| 代表者役職名 | Executive Chairman of the Board 取締役会長 |
| 電話番号 | +1 617-714-4096 |
| 設立年月日 | 41730 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2018年 |
| 従業員数 | 56人 |
| url | www.surfaceoncology.com |
| nasdaq_url | https://www.nasdaq.com/symbol/surf |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -15.23000 |
| 終値（lastsale） | 9.08 |
| 時価総額（marketcap） | 250739324.04 |
| 時価総額 | 時価総額（百万ドル） 231.96150 |
| 売上高 | 売上高（百万ドル） 52.88200 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 46.40750 |
| 当期純利益 | 当期純利益（百万ドル） -21.92600 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Surface Oncology Inc revenues increased from $7.9M to $47.9M. Net income applicable to common stockholders totaled $8.3M vs. loss of $15.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects Interest and other income (expense) net increase from $262K to $900K (income). |
SURFのテクニカル分析
SURFのニュース
Surface Oncology GAAP EPS of -$0.35 misses by $0.03 2023/03/09 12:16:34 Seeking Alpha
Surface Oncology press release (SURF): Q4 GAAP EPS of -$0.35 misses by $0.03.As of December 31, 2022, cash, cash equivalents and marketable securities were $124.8 million, compared…
Surface Oncology Reports Financial Results and Corporate Highlights for Fourth Quarter and Full Year 2022 2023/03/09 12:00:00 GlobeNewswire
SRF388 clinical program advancing well; updated clinical data expected in the first half of 2023
Blustering Stocks Grabbing Investor’s Attention: Science 37 Holdings, Inc. (NASDAQ:SNCE), Surface Oncology, Inc. (NASDAQ:SURF) 2023/02/21 14:42:38 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Blustering Stocks Grabbing Investor’s Attention: Science 37 Holdings, Inc. (NASDAQ:SNCE), Surface Oncology, Inc. (NASDAQ:SURF) appeared first on Stocks Equity .
Surface Oncology Inc. (NASDAQ: SURF) Is Under Pressure Due To Weak Fundamental Momentum. 2023/02/20 18:00:00 Marketing Sentinel
In the last trading session, 0.14 million Surface Oncology Inc. (NASDAQ:SURF) shares changed hands as the company’s beta touched 1.64. With the company’s per share price at $0.79 changed hands at -$0.01 or -0.50% during last session, the market valuation stood at $46.86M. SURF’s last price was a discount, traded about -370.89% off its 52-week … Surface Oncology Inc. (NASDAQ: SURF) Is Under Pressure Due To Weak Fundamental Momentum. Read More »
GSK plc – Consensus Indicates Potential 26.1% Upside 2023/02/01 12:52:29 DirectorsTalk
GSK plc found using ticker (GSK) have now 4 analysts in total covering the stock. The consensus rating is ''Hold''. The target price ranges between 63.75 and 36.2 calculating the mean target price we have 44.29. Now with the previous closing price of 35.12 this now indicates there is a potential upside of 26.1%. The 50 day moving average now sits at 35 and the 200 moving average now moves to 37.32. The market capitalisation for the company is $72,181m. You can visit the company''s website by visiting: https://www.gsk.com [stock_market_widget type="chart" template="basic" color="green" assets="GSK" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $91,028m based on the market concensus. GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally.
Surface Oncology PT Lowered to $3 at Wedbush 2022/11/02 20:53:01 Investing.com
https://www.investing.com/news/pro/surface-oncology-pt-lowered-to-3-at-wedbush-432SI-2930025
Surface Oncology letting go of 20% of workforce as it pauses solid tumors candidate 2022/11/02 18:23:58 Seeking Alpha
Surface Oncology (SURF) is laying off about 20% of its employees and pausing developing of SRF617, a phase 2 candidate targeting CD39 for solid tumors.The company is focusing resources…
Surface Oncology Inc. (SURF) can excel with these strategies 2022/11/02 15:32:00 US Post News
A share of Surface Oncology Inc. (NASDAQ:SURF) closed at $1.35 per share on Tuesday, up from $1.24 day before. While Surface Oncology Inc. has overperformed by 8.87%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, SURF fell by -82.05%, with highs and lows ranging from $7.97 […]
Recap: Surface Oncology Q3 Earnings 2022/11/02 12:22:04 Benzinga
Surface Oncology (NASDAQ: SURF ) reported its Q3 earnings results on Wednesday, November 2, 2022 at 06:22 AM. Here''s what investors need to know about the announcement. Earnings Surface Oncology beat estimated earnings by 17.02%, reporting an EPS of $-0.39 … Full story available on Benzinga.com
Surface Oncology Announces Promising SRF388 Monotherapy Data in Non-Small Cell Lung Cancer (NSCLC), Opening Second Stage of Monotherapy Trial and NSCLC Pembrolizumab Combination Cohort 2022/11/02 10:30:00 GlobeNewswire
– Two confirmed partial responses to SFR388 monotherapy treatment in squamous NSCLC; third patient with NSCLC experienced durable disease stabilization for over a year –
GSK plc – Consensus Indicates Potential 88.4% Upside 2022/09/28 10:46:39 DirectorsTalk
GSK plc with ticker code (GSK) have now 3 analysts in total covering the stock. The consensus rating is ''Buy''. The target price ranges between 63.75 and 36 calculating the average target price we see 54.29. Now with the previous closing price of 28.82 this now indicates there is a potential upside of 88.4%. There is a 50 day moving average of 35.7 and the 200 day MA is 41.68. The company has a market capitalisation of $57,907m. Visit the company website at: https://www.gsk.com [stock_market_widget type="chart" template="basic" color="green" assets="GSK" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $109,083m based on the market concensus. GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
Surface Oncology Inc. (NASDAQ:SURF) Rises 4.27%, But An Additional Surge May Follow. 2022/09/24 14:00:00 Marketing Sentinel
In last trading session, Surface Oncology Inc. (NASDAQ:SURF) saw 0.47 million shares changing hands with its beta currently measuring 1.64. Company’s recent per share price level of $1.10 trading at $0.05 or 4.27% at ring of the bell on the day assigns it a market valuation of $68.53M. That closing price of SURF’s stock is … Surface Oncology Inc. (NASDAQ:SURF) Rises 4.27%, But An Additional Surge May Follow. Read More »
GSK plc – Consensus Indicates Potential 67.3% Upside 2022/09/14 14:01:41 DirectorsTalk
GSK plc with ticker code (GSK) have now 3 analysts in total covering the stock. The consensus rating is ''Buy''. The target price ranges between 63.75 and 36 with a mean TP of 54.29. Given that the stocks previous close was at 32.45 this now indicates there is a potential upside of 67.3%. The 50 day moving average now sits at 38.06 while the 200 day moving average is 42.24. The company has a market capitalisation of $65,098m. Find out more information at: https://www.gsk.com [stock_market_widget type="chart" template="basic" color="green" assets="GSK" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $108,912m based on the market concensus. GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
Surface Oncology to Participate in the Baird 2022 Global Healthcare Conference 2022/09/07 20:30:00 GlobeNewswire
CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief executive officer, will participate in a fireside chat at the Baird 2022 Global Healthcare Conference on Wednesday, September 14, 2022, at 10:15 a.m. ET.
GSK plc – Consensus Indicates Potential 70.5% Upside 2022/09/07 11:40:36 DirectorsTalk
GSK plc found using ticker (GSK) have now 3 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The range between the high target price and low target price is between 63.75 and 36 with the average target price sitting at 54.29. Given that the stocks previous close was at 31.85 this is indicating there is a potential upside of 70.5%. The day 50 moving average is 39 while the 200 day moving average is 42.44. The company has a market capitalisation of $64,948m. You can visit the company''s website by visiting: https://www.gsk.com [stock_market_widget type="chart" template="basic" color="green" assets="GSK" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $110,707m based on the market concensus. GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally.